Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, parallel-group, multicentre, phase III study to assess the effect of esomeprazole 20 and 40 mg od versus placebo on the occurrence of peptic ulcers during 26 weeks in subjects on continuous low dose acetylsalicylic acid (ASA).

Next Previous
Trial Profile

A randomized, double-blind, parallel-group, multicentre, phase III study to assess the effect of esomeprazole 20 and 40 mg od versus placebo on the occurrence of peptic ulcers during 26 weeks in subjects on continuous low dose acetylsalicylic acid (ASA).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications NSAID-induced ulcer
  • Focus Registrational; Therapeutic Use
  • Acronyms OBERON
  • Sponsors AstraZeneca

Most Recent Events

  • 17 Mar 2011 Results published in the Heart.
  • 25 Nov 2009 Results presented at GASTRO 2009.
  • 30 May 2009 Results have been presented at DDW 2009.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top